COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR Webinar: NCI's Antibody Program

Antibodies are among the most commonly used tools in Antibody Program Webinar Announcementthe biological sciences - put to work in many experiments to identify and isolate other molecules.  NCI’s Antibody Program has developed more than 500 available antibodies that have been designed and optimized, with the vast majority developed as fit-for-purpose reagents.  The CPTAC Antibody Portal serves as a NCI community resource that provides access to a large number of standardized renewable affinity reagents (to cancer-associated targets) and accompanying characterization data.

Join Dr. Tara Hiltke Wednesday, January 22nd at 1:00 p.m. to find out more about the antibody program, show participants how to navigate the newly re-vamped portal, as well as discuss the "Request For Target" antibody submission requirements through the NCI Antibody Characterization Program. Registration is required.

This webinar is brought to you by the Office of Cancer Clinical Proteomics Research (OCCPR). OCCPR aims to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advancing proteome/proteogenome science and technology development through community resources (data and reagents), and accelerating the translation of molecular findings into the clinic.